Results 21 to 30 of about 119,295 (311)

Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma

Radiology and Oncology, 2018
BRAF, NRAS and c-KIT mutations are characteristics of tumour tissues that influence on treatment decisions in metastatic melanoma patients. Mutation frequency and their correlation with histological characteristics in Slovenian population have not been ...
Moltara Maja Ebert, Novakovic Srdjan, Boc Marko, Bucic Marina, Rebersek Martina, Zadnik Vesna, Ocvirk Janja   +6 more
doaj   +1 more source

ToBRAFor Not toBRAF: Is That Even a Question Anymore? [PDF]

Journal of Neuropathology & Experimental Neurology, 2013
Alterations in BRAF have been discovered in most pediatric low-grade gliomas. Because the field has moved quickly during the past few years, there is not yet widespread awareness about what B-Raf normally does, how the BRAF gene is modified in gliomas, why mutant proteins promote gliomagenesis, and what an abnormal BRAF result means for diagnosis ...
openaire   +2 more sources

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma [PDF]

Molecular & Cellular Oncology, 2015
Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independent erythropoietin-producing hepatocellular receptor A2
Smalley, Keiran SM, Fedorenko, Inna V
openaire   +2 more sources

Younger Than 55 Years Old and BRAF V600E Mutation are Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinomas ≤1.0 cm but Not in >1.0 cm

International Journal of General Medicine, 2023
Yeqian Lai,1,2 Yihua Gu,1,2 Ming Yu,1,2 Jiaqin Deng1,2 1Department of Thyroid Surgery, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China; 2Guangdong Provincial Key Laboratory of Precision Medicine and ...
Lai Y, Gu Y, Yu M, Deng J
doaj  

Somatic mutations in colorectal cancer: regional experience

Consilium Medicum, 2022
Introduction. Colorectal cancer is one of the most common malignant neoplasms in economically developed countries, ranking 3rd and 2nd in the structure of morbidity and mortality, respectively. Current knowledge about the molecular features of colorectal
Nikolai A. Ognerubov, Elena N. Ezhova
doaj   +1 more source

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations [PDF]

New England Journal of Medicine, 2012
Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.In this open-label study ...
Flaherty, Keith T, Infante, Jeffery R, Daud, Adil, Gonzalez, Rene, Kefford, Richard F, Sosman, Jeffrey, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Ibrahim, Nageatte, Kudchadkar, Ragini, Burris, Howard A, Falchook, Gerald, Algazi, Alain, Lewis, Karl, Long, Georgina V, Puzanov, Igor, Lebowitz, Peter, Singh, Ajay, Little, Shonda, Sun, Peng, Allred, Alicia, Ouellet, Daniele, Kim, Kevin B, Patel, Kiran, Weber, Jeffrey   +25 more
openaire   +4 more sources

The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis

, 2022
Objectives: Immune-checkpoint inhibitors (ICI) and targeted-therapies (TT) have become standard options for BRAF-V600 metastatic melanomas (MM). Recently, randomized trials (RCT) addressed the efficacy of combined approaches, with conflicting results. We
Marina Sahade, Mauricio Fernando Silva Almeida Ribeiro, Olavo Feher, Artur Katz, Allan Andresson Lima Pereira, Mariana Scaranti, Luiza Dib Batista Bugiato Faria, Rodrigo Ramella Munhoz, Camila Bragança Xavier, Tatiana Strava Correa, David Queiroz Borges Muniz, Gustavo dos Santos Fernandes   +11 more
core   +1 more source

V600e braf inhibition induces cytoprotective autophagy through ampk in thyroid cancer cells [PDF]

, 2021
The dysregulation of autophagy is important in the development of many cancers, including thyroid cancer, whereV600E BRAF is a main oncogene. Here, we analyse the effect ofV600E BRAF inhibition on autophagy, the mechanisms involved in this regulation and
Díaz-Gago, Sergio, Lasa Benito, Marina Paloma, Díaz Gago, Sergio, Lasa, Marina, Marina Lasa, Gallego, Beatriz, Chiloeches, Antonio, Baquero Valls, Pablo, Sergio Díaz-Gago, Gallego Tamayo, Beatriz, Antonio Chiloeches, Chiloeches Gálvez, Antonio, Beatriz Gallego, Jiménez-Mora, Eva, Baquero, Pablo, Jiménez Mora, Eva María, Eva Jiménez-Mora, Pablo Baquero   +17 more
core   +1 more source

The frequency of mutations in advanced thyroid cancer in Japan: a single-center study

Endocrine Journal
We analyzed the outcomes of genetic testing to study the frequency of mutations in advanced thyroid cancer in Japan. Patients (n = 96) with unresectable or metastatic thyroid carcinoma were included for retrospective chart review.
Soji Toda, Hiroyuki Iwasaki, Yoichiro Okubo, Hiroyuki Hayashi, Mei Kadoya, Hiroyuki Takahashi, Tomoyuki Yokose, Yukihiko Hiroshima, Katsuhiko Masudo   +8 more
doaj   +1 more source

European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender

BJS (British Journal of Surgery), EarlyView., 2020
Recommendations for clinical and molecular identification of LS, surgical and endoscopic management of LS‐associated colorectal cancer and preventive measures for cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer spectrum.
T. T. Seppälä, A. Latchford, I. Negoi, A. Sampaio Soares, R. Jimenez‐Rodriguez, L. Sánchez‐Guillén, D. G. Evans, N. Ryan, E. J. Crosbie, M. Dominguez‐Valentin, J. Burn, M. Kloor, M. von Knebel Doeberitz, F. J. B. van Duijnhoven, P. Quirke, J. R. Sampson, P. Møller, G. Möslein, on behalf of the European Hereditary Tumour Group (EHTG) and European Society of Coloproctology (ESCP)   +18 more
wiley   +1 more source